நோவர்த்திச் பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோவர்த்திச் பெருநிறுவன தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோவர்த்திச் பெருநிறுவன தகவல்தொடர்புகள் Today - Breaking & Trending Today

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease


Share this article
Share this article
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.
Ilaris, an interleukin-1 beta inhibitor, provides a new mode of treatment for this disease 
which previously had limited options.
1,2
DORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris
®
 (canakinumab) for the treatment of active Still s disease, including adult-onset Still s disease (AOSD)
1. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications ....

Julie Schneiderman , Derek Haaland , Andrea Marazzi , Novartis Pharmaceuticals Canada , Novartis Pharmaceuticals Canada Inc , Novartis Corporate Communications , Health Canada , Pharmaceuticals Canada , Systemic Juvenile Idiopathic Arthritis , Country Head , Novartis Pharmaceuticals , Periodic Fever Syndromes , Cryopyric Associated Periodic Syndrome , Pharmaceuticals Canada Inc , Clinical Risk Management , Adult Onset Still , Onset Still , Autoimmunity Reviews , Novartis Media Relations , ஜூலி ஸ்ச்சினெதெர்மன் , ஆண்ட்ரியா மராஸி , நோவர்த்திச் மருந்துகள் கனடா , நோவர்த்திச் மருந்துகள் கனடா இன்க் , நோவர்த்திச் பெருநிறுவன தகவல்தொடர்புகள் , ஆரோக்கியம் கனடா , மருந்துகள் கனடா ,